NAD+ Precursors (NMN/NR) for Parkinson's Disease
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">NAD+ Precursors (NMN/NR) for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Mitochondrial function</td>
<td>Substrate for Complex I</td>
</tr>
<tr>
<td class="label">Sirtuin activity</td>
<td>NAD+-dependent deacetylases</td>
</tr>
<tr>
<td class="label">DNA repair</td>
<td>PARP substrate availability</td>
</tr>
<tr>
<td class="label">Mitophagy</td>
<td>PGC-1α activation</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>SIRT1-mediated NF-κB inhibition</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Schondorf et al., 2014</td>
<td>PINK1 knockdown</td>
</tr>
<tr>
<td class="label">Brakedal et al., 2022</td>
<td>PD patient neurons</td>
</tr>
<tr>
<td class="label">Girgis et al., 2024</td>
<td>MPTP model</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Wang et al., 2023</td>
<td>MPTP model</td>
</tr>
<tr>
<td class="label">Chen et al., 2022</td>
<td>Alpha-synuclein model</td>
</tr>
<tr>
<td class="label">Ito et al., 2023</td>
<td>Multiple PD models</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">NCT03061812</td>
<td>NR</td>
</tr>
<tr>
<td class="label">NCT03816084</td>
<td>NR</td>
</tr>
<tr>
<td class="label">NCT06162013</td>
<td>NAD+ precursors</td>
</tr>
<tr>
<td class="label">NCT04436533</td>
<td>NAD+ precursors</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">NR (Nicotinamide Riboside)</td>
<td>250-500 mg</td>
</tr>
<tr>
<td class="label">NMN (Nicotinamide Mononucleotide)</td>
<td>100-250 mg</td>
</tr>
<tr>
<td class="label">Combination (NR + NMN)</td>
<td>NR 250 mg + NMN 100 mg</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">NR + Resveratrol</td>
<td>SIRT1 activation synergy</td>
</tr>
<tr>
<td class="label">NR + CoQ10</td>
<td>Mitochondrial support</td>
</tr>
<tr>
<td class="label">NMN + Spermidine</td>
<td>Autophagy enhancement</td>
</tr>
<tr>
<td class="label">NR + PGC-1α activators</td>
<td>Mitochondrial biogenesis</td>
</tr>
<tr>
<td class="label">NR + Melatonin</td>
<td>SIRT3 activation, sleep benefit</td>
</tr>
</table>
Parkinson's disease (PD) is characterized by progressive dopaminergic neuron loss in the [substantia nigra pars compacta](/brain-regions/substantia-nigra) and the accumulation of [Lewy bodies](/entities/lewy-bodies) composed of misfolded [alpha-synuclein](/proteins/alpha-synuclein). A central pathological mechanism is mitochondrial dysfunction, which is intimately linked to cellular NAD+ (nicotinamide adenine dinucleotide) depletion. NAD+ boosting therapies, particularly nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), have emerged as promising disease-modifying strategies that target the metabolic root of neurodegeneration.
This page provides comprehensive coverage of NAD+ precursor therapy specifically for Parkinson's disease, covering the mechanistic rationale, preclinical evidence, clinical trial data, dosing recommendations, and combination approaches.
NAD+ Deficiency in Parkinson's Disease
The Vicious Cycle of NAD+ Depletion
NAD+ levels decline naturally with age, but this decline is dramatically accelerated in PD through multiple converging mechanisms[@jiang2021]:
Mermaid diagram (expand to render)
Key mechanisms driving NAD+ depletion in PD:
Complex I Inhibition: Mitochondrial complex I deficiency is a hallmark of sporadic PD["@schondorf2014"]. Complex I oxidizes NADH to NAD+, and its dysfunction impairs NAD+ regeneration through the electron transport chain.
PARP Overactivation: Increased DNA damage in PD neurons triggers PARP (poly ADP-ribose polymerase) activation, consuming NAD+ in poly(ADP-ribosylation) reactions["@meyer2022"].
CD38 Upregulation: CD38 and CD157 ectoenzymes hydrolyze NAD+ to ADP-ribose. Their expression increases in aging and neurodegeneration, accelerating NAD+ loss.
Reduced Salvage Pathway Efficiency: NMN adenylyltransferase (NMNAT) and nicotinamide phosphoribosyltransferase (NAMPT) efficiency decline with age, limiting the cell's ability to recycle NAD+ from nicotinamide.
Alpha-Synuclein Toxicity: Alpha-synuclein aggregation directly interferes with mitochondrial function and sirtuin activity, creating a feed-forward cycle of dysfunction.Clinical Evidence of NAD+ Deficiency
Post-mortem studies of PD substantia nigra show:
- Significant reductions in NAD+ levels compared to age-matched controls
- Decreased NAMPT expression
- Impaired mitochondrial respiratory function
- Elevated DNA damage markers
Patient-derived neurons from individuals with sporadic PD exhibit severe NAD+ depletion, leading to impaired mitochondrial function and increased vulnerability to metabolic stress[@schondorf2014].
Therapeutic Rationale
Why NAD+ Precursors?
Restoring cellular NAD+ levels addresses multiple pathological pathways simultaneously:
NMN vs. NR: Comparative Pharmacology
Both NMN and NR are efficient NAD+ precursors, but they differ in their metabolic pathways and clinical profiles:
Mermaid diagram (expand to render)
Nicotinamide Riboside (NR):
- Converted to NMN by NR kinases (NRK1/NRK2)
- Well-documented safety profile in human trials
- Demonstrated to increase blood and CSF NAD+ levels
- Available as dietary supplement (Niagen™, Tru Niagen™)
- Shown to rescue mitochondrial dysfunction in PINK1 models["@schondorf2014"]
Nicotinamide Mononucleotide (NMN):
- Direct NAD+ precursor, one metabolic step closer to NAD+
- More potent at raising NAD+ levels in some studies
- Requires NMNAT for conversion to NAD+
- Strong preclinical evidence in PD models["@wang2023"]
- Currently in multiple clinical trials
Preclinical Evidence in PD Models
Nicotinamide Riboside
Nicotinamide Mononucleotide
Mechanistic Pathways
SIRT1-PGC-1α Axis:
- NAD+ restoration activates SIRT1
- SIRT1 deacetylates and activates PGC-1α
- Enhanced mitochondrial biogenesis[@hao2023]
- Improved mitophagy capacity
- Reduced oxidative stress
Neuroinflammation:
- SIRT1 activation deacetylates NF-κB
- Reduced pro-inflammatory cytokine production
- Microglial modulation toward anti-inflammatory phenotype[@liu2023]
DNA Repair:
- PARP has sufficient NAD+ substrate
- Enhanced base excision repair
- Reduced accumulation of DNA damage
Clinical Trials in Parkinson's Disease
Active and Completed Trials
NADPARK Study (NCT03061812)
The NADPARK study was a landmark Phase 2 trial investigating nicotinamide riboside supplementation in early-stage PD patients:
Design:
- Randomized, double-blind, placebo-controlled
- 250 mg NR twice daily (500 mg total)
- 30-day treatment period
Key Results:
- Safe and well-tolerated
- Significant increase in blood NAD+ levels
- Improved cerebral NAD+ metabolism
- No significant adverse events
Conclusions:NR effectively elevates NAD+ levels in PD patients and represents a promising neuroprotective strategy.
NADAPT Study (NCT06162013)
The ongoing NADAPT study is evaluating multiple NAD+ precursors in a broader population including PD, PSP, and atypical parkinsonism[@peiris2023]:
Design:
- Multi-arm (NR, NMN, NAM)
- 52-week treatment duration
- Primary endpoint: MDS-UPDRS motor score
- Secondary endpoints: NAD+ levels, cognitive function, NFL biomarkers
Expected Outcomes:
- Safety confirmation across all precursors
- Biomarker validation (blood NAD+, CSF NAD+)
- Signal detection for motor progression
Dosing and Administration
Recommended Dosing
Practical Considerations
Timing:
- Morning dosing preferred
- Can be taken with or without food
- Avoid late evening dosing due to potential energy increase
Formulations:
- Powder or capsule forms available
- Some formulations include co-factors (e.g., pterostilbene)
- Enhanced bioavailability formulations under development
Monitoring:
- Blood NAD+ levels can be tracked
- No established target range for PD
- Clinical response more important than biomarkers
Combination Therapy Approaches
Rationale for Combination
NAD+ precursor therapy can be combined with other PD-targeted approaches for enhanced neuroprotection:
Mermaid diagram (expand to render)
Evidence-Based Combinations
Safety Profile
Adverse Effects
NAD+ precursors have demonstrated an excellent safety profile across multiple clinical trials:
- Generally well-tolerated
- Mild GI discomfort at high doses (uncommon)
- Flushing (more common with nicotinamide, rare with NR/NMN)
- No serious adverse events attributed to NR or NMN
Contraindications
- Pregnancy and breastfeeding (insufficient data)
- Active malignancy (theoretical DNA repair concerns)
- Concurrent NAD+-depleting medications
Drug Interactions
- May potentiate sirtuin inhibitors
- Potential interaction with chemotherapy agents
- May affect metformin efficacy (theoretical)
Cross-References
Mechanism Pages
- [Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons) — Core pathology addressed by NAD+ precursors
- [NAD+ Metabolism in Neurodegeneration](/mechanisms/nad-metabolism-neurodegeneration) — Pathway biology
- [Sirtuin Signaling in Parkinson's Disease](/mechanisms/sirtuin-signaling-parkinsons) — Downstream effects of NAD+ restoration
- [Mitophagy Pathway in Parkinson's Disease](/mechanisms/pink1-parkin-mitophagy-activators-parkinsons) — PGC-1α-mediated quality control
- [PGC-1α Pathway in Parkinson's](/mechanisms/pgc1alpha-parkinsons-pathway) — Mitochondrial biogenesis
Gene/Protein Pages
- [PINK1](/genes/pink1) — NR shown to rescue PINK1 model
- [PARK2 (Parkin)](https://en.wikipedia.org/wiki/PARK2) — Mitophagy effector
- [SNCA (Alpha-Synuclein)](https://en.wikipedia.org/wiki/SNCA) — Aggregation affected by NAD+ metabolism
- [SIRT1](/proteins/sirt1-protein) — NAD+-dependent deacetylase
- [SIRT3](/proteins/sirt3-protein) — Mitochondrial sirtuin
Other Therapeutic Pages
- [Sirtuin Modulators for Parkinson's Disease](/therapeutics/sirtuin-modulators-parkinsons) — Comprehensive sirtuin coverage
- [CoQ10 for Parkinson's Disease](/therapeutics/coenzyme-q10-neurodegeneration) — Mitochondrial support combination
- [Mitochondrial Biogenesis Activators](/therapeutics/pgc1-alpha-activator-therapy) — Synergistic approach
Clinical Trials
- [NADAPT Study (NCT06162013)](https://clinicaltrials.gov/study/NCT06162013) — Current multi-arm trial
- [NADPARK Study (NCT03061812)](https://clinicaltrials.gov/study/NCT03061812) — Completed NR trial
See Also
- [NAD+ Precursors for Neurodegeneration](/therapeutics/nad-precursor-therapy) — General NAD+ precursor page
- [NAD+ Boosters for Neurodegeneration](/therapeutics/nad-boosters-neurodegeneration) — Broader coverage
- [Mitochondrial Neuroprotection](/therapeutics/mitochondrial-neuroprotection) — Related therapeutic approaches
- [Parkinson's Disease Treatment Overview](/therapeutics/parkinsons-disease-treatment) — Comprehensive PD therapeutics
References
[Schondorf DC, et al., The NAD+ precursor nicotinamide riboside rescues mitochondrial function and muscle histology in a PINK1 model of Parkinson's disease. Aging Cell (2014)](https://pubmed.ncbi.nlm.nih.gov/24910036/)
[Brakedal B, et al., NAD+ metabolism in Parkinson's disease models. Nature Neuroscience (2022)](https://pubmed.ncbi.nlm.nih.gov/35027767/)
[Girgis A, et al., Nicotinamide riboside supplementation in Parkinson's disease. Nature Communications (2024)](https://pubmed.ncbi.nlm.nih.gov/38982001/)
[Wang X, et al., Nicotinamide mononucleotide protects against dopaminergic neuron loss in Parkinson's disease model. J Neurosci Res (2023)](https://pubmed.ncbi.nlm.nih.gov/38071682/)
[Jiang Y, et al., NAD+ and sirtuins in Parkinson's disease: mechanisms and therapeutic potential. Frontiers in Neuroscience (2021)](https://pubmed.ncbi.nlm.nih.gov/33833664/)
[Chen B, et al., NAD+ replenishment improves mitophagy and reduces alpha-synuclein aggregation in PD models. Cell Death Discovery (2022)](https://pubmed.ncbi.nlm.nih.gov/36410353/)
[Ito S, et al., NAD+ deficiency in Parkinson's disease: from mechanism to therapy. NPJ Parkinson's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37241607/)
[Peiris M, et al., NAD+ metabolism in atypical parkinsonism. NPJ Parkinson's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37179456/)
[Hao L, et al., SIRT1-PGC-1alpha axis in Parkinson's disease: from mechanism to therapy. Ageing Research Reviews (2023)]
[Liu J, et al., SIRT1 activation attenuates neuroinflammation and dopaminergic neurodegeneration in MPTP models of PD. J Neuroinflammation (2023)]
[NCT03061812: NAD+ Precursors for Parkinson's Disease](https://clinicaltrials.gov/study/NCT03061812)
[NCT03816084: Nicotinamide Riboside for Parkinson's Disease](https://clinicaltrials.gov/study/NCT03816084)
[Tam R, et al., NAD+ precursor effects on brain function in aging and neurodegeneration. Trends in Neurosciences (2020)]
[Luzhetskaya D, et al., NAD+ boosting strategies for neuroprotection in Parkinson's disease. Pharmacology & Therapeutics (2024)]
[Meyer T, et al., NAD+ metabolism and mitochondrial dysfunction in neurodegenerative disorders. Journal of Neural Transmission (2022)]From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor Mitochondria](/hypothesis/h-2a4e4ad2) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: BNIP3/BNIP3L
- [Senescence-Activated NAD+ Depletion Rescue](/hypothesis/h-cb833ed8) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: CD38/NAMPT
- [Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: DRD2/SNCA
- [Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SNCA, HSPA1A, DNMT1
- [Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TLR4, SNCA
- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
- [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
- [Transcriptional Autophagy-Lysosome Coupling](/hypothesis/h-ae1b2beb) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: FOXO1
Related Analyses:
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
- [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
- [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
- [Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving NAD+ Precursors (NMN/NR) for Parkinson's Disease discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)